Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Karyopharm Therapeutics Inc. (KPTI)

Karyopharm to be delisted from Nasdaq after Chapter 11 filing; trading suspends Nov. 11

Negative Impact 5 of 5 legal/regulatory Written later

Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on November 2, 2026, and Nasdaq notified the company on November 4 that its common stock will be delisted. The company will not appeal, and the stock is expected to move to an over-the-counter market under the symbol KPTIQ. The filing says the proposed reorganization plan gives common stock and Series A preferred holders no payment, so existing equity is expected to have no value.

Key points

  • Nasdaq trading in common stock suspends at the opening of business on November 11, 2026.
  • Common stock expected to trade over the counter under the symbol KPTIQ on or after November 11, 2026.
  • Joint prepackaged Chapter 11 plan filed November 2, 2026 provides no distribution to common or 0% Series A Convertible Perpetual Preferred Stock holders.
  • The company expects existing equity securities to have no value and holders to face a complete loss.

The filing

CompanyKaryopharm Therapeutics Inc. (KPTI)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:00 AM ET
Accession number0001193125-26-448516

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.